News
FDA extends PDUFA date for review of Rinvoq in the treatment of atopic dermatitis. -AbbVie
AbbVie announced that the FDA has extended the review period for the supplemental New Drug Application (sNDA) for Rinvoq (upadacitinib) in the treatment of adults and adolescents with moderate to severe atopic dermatitis.
The Prescription Drug User Fee Act (PDUFA) action date has been extended three months to early Q3 2021.
Condition: Atopic Dermatitis (Eczema)
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.